Ocrevus will be biggest seller of 2017's new drugs, report says

10 April 2017

As many as eight of the new therapeutics set to enter markets this year will cross the $1 billion annual sales threshold by 2021, according to a report from Clarivate Analytics.

The intelligence provider’s report, titled Blockbuster Outlook 2017, predicts that Ocrevus (ocrelizumab), a multiple sclerosis (MS) drug developed by Genentech, a unit of Swiss pharma giant Roche (ROG: SIX), will top this list.

It is predicted that Roche will earn annual sales in 2021 of up to $3.33 billion from Ocrevus, which was approved to treat adult patients with relapsing and primary progressive forms of MS by the US Food and Drug Administration (FDA) last month.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK